[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
Current concepts for the treatment of somatostatin receptor positive tumours have not been very motivating up to now. A promising alternative could be the new peptidic vector DOTA-D-Phe1-Tyr3-Octreotide (DOTATOC) recently developed in Basel. It may be labelled with the beta-emitter yttrium-90 (90Y) for internal radiotherapy after systemic application. Pilot therapy studies have shown convincing results with this new radiopharmaceutical. These studies are presented with regard to efficacy and possible toxicity. In summary, the new receptor-mediated 90Y-DOTATOC therapy led to tumour response in the majority of patients, and only in some receiving high cumulative doses of > 200 mCi per m2 body surface renal and hematological toxicity due to irradiation occurred. For the reduction of renal accretion, concepts with concomitant amino acid infusions containing L-lysine in a higher concentration are currently under way.
Otte
A
A
Klinik und Institut für Nuklearmedizin, Universitätskliniken, Kantonsspital Basel. otte@ubaclu.unibas.ch
Herrmann
R
R
Mäcke
H R
HR
Müller-Brand
J
J
D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000737:chemistry / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010865:Pilot Projects; D011446:Prospective Studies; D011832:Radiation Injuries / Q000209:etiology; D011877:Radionuclide Imaging; D011879:Radiotherapy Dosage; D017481:Receptors, Somatostatin / Q000032:analysis; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
D017481:Receptors, Somatostatin; D015021:Yttrium Radioisotopes; D015282:Octreotide; C106246:Edotreotide